

# Supplementary Materials

**Table S1.** Distribution of symptoms among symptomatic infections (during positivity) - First infections versus reinfections - Bivariate Analysis.

| Symptoms during positivity | First infections<br>n=1,855 |        | Reinfections<br>n=150 |        | Total symptomatic infections<br>n=2,005 |        | OR (95%CI)                | p                |
|----------------------------|-----------------------------|--------|-----------------------|--------|-----------------------------------------|--------|---------------------------|------------------|
|                            | n                           | (%)    | n                     | (%)    | n                                       | (%)    |                           |                  |
| Fever                      | 1,078                       | (58.1) | 72                    | (48.0) | 1,150                                   | (57.4) | <b>0.67 (0.48 - 0.93)</b> | <b>0.016</b>     |
| Fatigue and Malaise        | 1,394                       | (75.1) | 89                    | (59.3) | 1,483                                   | (74.0) | <b>0.48 (0.34 - 0.68)</b> | <b>&lt;0.001</b> |
| Myalgia-Arthralgia         | 1,079                       | (58.2) | 69                    | (46.0) | 1,148                                   | (57.3) | <b>0.61 (0.44 - 0.86)</b> | <b>0.004</b>     |
| Cough                      | 1,015                       | (54.7) | 69                    | (46.0) | 1,084                                   | (54.1) | <b>0.71 (0.51 - 0.98)</b> | <b>0.041</b>     |
| Headache                   | 983                         | (53.0) | 65                    | (43.3) | 1,048                                   | (52.3) | <b>0.68 (0.49 - 0.95)</b> | <b>0.023</b>     |
| Runny Nose                 | 841                         | (45.3) | 61                    | (40.7) | 902                                     | (45.0) |                           | ns               |
| Sore Throat                | 800                         | (43.1) | 68                    | (45.3) | 868                                     | (43.3) |                           | ns               |
| Chills                     | 592                         | (31.9) | 41                    | (27.3) | 633                                     | (31.6) |                           | ns               |
| Loss of Taste              | 507                         | (27.3) | 18                    | (12.0) | 525                                     | (26.2) | <b>0.36 (0.22 - 0.60)</b> | <b>&lt;0.001</b> |
| Loss of Smell              | 486                         | (26.2) | 15                    | (10.0) | 501                                     | (25.0) | <b>0.31 (0.18 - 0.54)</b> | <b>&lt;0.001</b> |
| Rhinitis                   | 532                         | (28.7) | 42                    | (28.0) | 574                                     | (28.6) |                           | ns               |
| Dyspnoea                   | 400                         | (21.6) | 19                    | (12.7) | 419                                     | (20.9) | <b>0.53 (0.32 - 0.86)</b> | <b>0.010</b>     |
| Lack of Appetite           | 278                         | (15.0) | 9                     | (6.0)  | 287                                     | (14.3) | <b>0.36 (0.18 - 0.72)</b> | <b>0.003</b>     |
| Difficulty Concentrating   | 248                         | (13.4) | 15                    | (10.0) | 263                                     | (13.1) |                           | ns               |
| Diarrhea                   | 234                         | (12.6) | 16                    | (10.7) | 250                                     | (12.5) |                           | ns               |
| Chest Pain                 | 204                         | (11.0) | 10                    | (6.7)  | 214                                     | (10.7) |                           | ns               |
| Insomnia                   | 212                         | (11.4) | 13                    | (8.7)  | 225                                     | (11.2) |                           | ns               |
| Anxious State              | 204                         | (11.0) | 9                     | (6.0)  | 213                                     | (10.6) |                           | ns               |
| Weight Loss                | 153                         | (8.2)  | 8                     | (5.3)  | 161                                     | (8.0)  |                           | ns               |
| Abdominal Pain             | 121                         | (6.5)  | 9                     | (6.0)  | 130                                     | (6.5)  |                           | ns               |
| Vomiting and Nausea        | 179                         | (9.6)  | 7                     | (4.7)  | 186                                     | (9.3)  | <b>0.46 (0.21 - 0.99)</b> | <b>0.041</b>     |
| Conjunctivitis             | 103                         | (5.6)  | 4                     | (2.7)  | 107                                     | (5.3)  |                           | ns               |
| Skin Lesions               | 31                          | (1.7)  | 2                     | (1.3)  | 33                                      | (1.6)  |                           | ns               |
| Lymphadenopathy            | 50                          | (2.7)  | 1                     | (0.7)  | 51                                      | (2.5)  |                           | ns               |
| Bleeding                   | 6                           | (0.3)  | 0                     | (0.0)  | 6                                       | (0.3)  |                           | ns               |
| Confusion                  | 59                          | (3.2)  | 2                     | (1.3)  | 61                                      | (3.0)  |                           | ns               |
| Aphasia                    | 18                          | (1.0)  | 0                     | (0.0)  | 18                                      | (0.9)  |                           | ns               |
| Memory Loss                | 87                          | (4.7)  | 9                     | (6.0)  | 96                                      | (4.8)  |                           | ns               |
| Dizziness                  | 93                          | (5.0)  | 6                     | (4.0)  | 99                                      | (4.9)  |                           | ns               |
| Seizures                   | 2                           | (0.1)  | 0                     | (0.0)  | 2                                       | (0.1)  |                           | ns               |
| Inability to Walk          | 31                          | (1.7)  | 2                     | (1.3)  | 33                                      | (1.6)  |                           | ns               |
| Fainting                   | 22                          | (1.2)  | 0                     | (0.0)  | 22                                      | (1.1)  |                           | ns               |
| Depression                 | 85                          | (4.6)  | 5                     | (3.3)  | 90                                      | (4.5)  |                           | ns               |

Legend: bold indicates statistically significant results; ns: not significative association

**Table S2.** Distribution of symptoms among infections with persistent symptoms (after the negative SARS-CoV-2 swab) - First infections versus reinfections - Bivariate analysis.

| Symptoms after negative SARS-CoV-2 swab | First infections<br>n=1,296 |        | Reinfections<br>n=98 |        | Total symptomatic infections<br>n=1,394 |        | p  |
|-----------------------------------------|-----------------------------|--------|----------------------|--------|-----------------------------------------|--------|----|
|                                         | n                           | (%)    | n                    | (%)    | n                                       | (%)    |    |
| Fatigue and Malaise                     | 644                         | (49.7) | 45                   | (45.9) | 689                                     | (49.4) | ns |
| Myalgia-Arthralgia                      | 286                         | (22.1) | 30                   | (30.6) | 316                                     | (22.7) | ns |
| Cough                                   | 267                         | (20.6) | 19                   | (19.4) | 286                                     | (20.5) | ns |
| Dyspnoea                                | 215                         | (16.6) | 17                   | (17.3) | 232                                     | (16.6) | ns |
| Difficulty Concentrating                | 177                         | (13.7) | 18                   | (18.4) | 195                                     | (14.0) | ns |
| Headache                                | 157                         | (12.1) | 13                   | (13.3) | 170                                     | (12.2) | ns |
| Loss of Taste                           | 127                         | (9.8)  | 4                    | (4.1)  | 131                                     | (9.4)  | ns |
| Loss of Smell                           | 141                         | (10.9) | 7                    | (7.1)  | 148                                     | (10.6) | ns |
| Runny Nose                              | 93                          | (7.2)  | 9                    | (9.2)  | 102                                     | (7.3)  | ns |
| Rhinitis                                | 83                          | (6.4)  | 3                    | (3.1)  | 86                                      | (6.2)  | ns |
| Insomnia                                | 107                         | (8.3)  | 12                   | (12.2) | 119                                     | (8.5)  | ns |
| Anxious State                           | 86                          | (6.6)  | 6                    | (6.1)  | 92                                      | (6.6)  | ns |
| Fever                                   | 10                          | (0.8)  | 0                    | (0.0)  | 10                                      | (0.7)  | ns |
| Chills                                  | 9                           | (0.7)  | 0                    | (0.0)  | 9                                       | (0.6)  | ns |
| Weight Loss                             | 21                          | (1.6)  | 0                    | (0.0)  | 21                                      | (1.5)  | ns |
| Abdominal Pain                          | 18                          | (1.4)  | 0                    | (0.0)  | 18                                      | (1.3)  | ns |
| Vomiting and Nausea                     | 22                          | (1.7)  | 3                    | (3.1)  | 25                                      | (1.8)  | ns |
| Diarrhea                                | 26                          | (2.0)  | 2                    | (2.0)  | 28                                      | (2.0)  | ns |
| Chest Pain                              | 40                          | (3.1)  | 2                    | (2.0)  | 42                                      | (3.0)  | ns |
| Sore Throat                             | 46                          | (3.5)  | 7                    | (7.1)  | 53                                      | (3.8)  | ns |
| Conjunctivitis                          | 14                          | (1.1)  | 1                    | (1.0)  | 15                                      | (1.1)  | ns |
| Skin Lesions                            | 9                           | (0.7)  | 0                    | (0.0)  | 9                                       | (0.6)  | ns |
| Lymphadenopathy                         | 5                           | (0.4)  | 1                    | (1.0)  | 6                                       | (0.4)  | ns |
| Bleeding                                | 1                           | (0.1)  | 0                    | (0.0)  | 1                                       | (0.1)  | ns |
| Confusion                               | 27                          | (2.1)  | 1                    | (1.0)  | 28                                      | (2.0)  | ns |
| Aphasia                                 | 5                           | (0.4)  | 0                    | (0.0)  | 5                                       | (0.4)  | ns |
| Memory Loss                             | 77                          | (5.9)  | 8                    | (8.2)  | 85                                      | (6.1)  | ns |
| Dizziness                               | 23                          | (1.8)  | 2                    | (2.0)  | 25                                      | (1.8)  | ns |
| Seizures                                | 1                           | (0.1)  | 0                    | (0.0)  | 1                                       | (0.1)  | ns |
| Inability to Walk                       | 6                           | (0.5)  | 1                    | (1.0)  | 7                                       | (0.5)  | ns |
| Fainting                                | 3                           | (0.2)  | 0                    | (0.0)  | 3                                       | (0.2)  | ns |
| Lack of Appetite                        | 20                          | (1.5)  | 0                    | (0.0)  | 20                                      | (1.4)  | ns |
| Depression                              | 40                          | (3.1)  | 4                    | (4.1)  | 44                                      | (3.2)  | ns |

Legend: ns: not significative association.

**Table S3.** Distribution of COVID-19-related symptoms - Logistic Multivariate Analysis.

|                                      |        | Symptomatic infections<br>n=2,005 | Fever n=1,150              |        |                           |              | Fatigue/Malaise n=1,483 |        |                           |              |
|--------------------------------------|--------|-----------------------------------|----------------------------|--------|---------------------------|--------------|-------------------------|--------|---------------------------|--------------|
|                                      |        |                                   | n.                         | (%)    | adjOR (95%CI)             | p            | n.                      | (%)    | adjOR (95%CI)             | p            |
| Sex                                  | Female | 1,589                             | 886                        | (55.8) | <b>0.76 (0.61 - 0.96)</b> | <b>0.020</b> | 1,202                   | (75.6) | <b>1.5 (1.18 - 1.91)</b>  | <b>0.001</b> |
|                                      | Male   | 416                               | 264                        | (63.5) | ref                       |              | 281                     | (67.5) | ref                       |              |
| Age class                            | ≤30    | 398                               | 240                        | (60.3) |                           | ns           | 295                     | (74.1) |                           | ns           |
|                                      | 31-49  | 717                               | 408                        | (56.9) |                           |              | 527                     | (73.5) |                           |              |
|                                      | >50    | 616                               | 343                        | (55.7) |                           |              | 472                     | (76.6) |                           |              |
|                                      | nr     | 274                               | 159                        | (58.0) |                           |              | 189                     | (69.0) |                           |              |
|                                      |        |                                   |                            |        |                           |              |                         |        |                           |              |
| Comorbidities                        | yes    | 460                               | 273                        | (59.3) |                           | ns           | 360                     | (78.3) | <b>1.33 (1.03 - 1.71)</b> | <b>0.031</b> |
|                                      | no     | 1,545                             | 877                        | (56.8) |                           |              | 1,123                   | (72.7) |                           |              |
| Reinfection                          | yes    | 150                               | 72                         | (48.0) | <b>0.62 (0.44 - 0.88)</b> | <b>0.007</b> | 89                      | (59.3) | <b>0.51 (0.36 - 0.73)</b> | <b>0.000</b> |
|                                      | no     | 1,855                             | 1,078                      | (58.1) | ref                       |              | 1,394                   | (75.1) | ref                       |              |
| Study phase                          | 1      | 87                                | 61                         | (70.1) | ref                       |              | 72                      | (82.8) |                           | ns           |
|                                      | 2      | 304                               | 178                        | (58.6) | 0.61 (0.37 - 1.03)        | 0.064        | 251                     | (82.6) |                           |              |
|                                      | 3      | 55                                | 28                         | (50.9) | <b>0.43 (0.20 - 0.93)</b> | <b>0.031</b> | 42                      | (76.4) |                           |              |
|                                      | 4      | 601                               | 296                        | (49.3) | <b>0.48 (0.25 - 0.92)</b> | <b>0.027</b> | 430                     | (71.5) |                           |              |
|                                      | 5      | 772                               | 483                        | (62.6) | 0.86 (0.44 - 1.65)        | 0.642        | 558                     | (72.3) |                           |              |
|                                      | nr     | 186                               | 104                        | (55.9) |                           |              | 130                     | (69.9) |                           |              |
|                                      |        |                                   |                            |        |                           |              |                         |        |                           |              |
| Vaccination status to the positivity | 0      | 356                               | 216                        | (60.7) |                           | ns           | 291                     | (81.7) |                           | ns           |
|                                      | 1      | 30                                | 20                         | (66.7) |                           |              | 23                      | (76.7) |                           |              |
|                                      | 2      | 135                               | 78                         | (57.8) |                           |              | 95                      | (70.4) |                           |              |
|                                      | 3      | 996                               | 560                        | (56.2) |                           |              | 721                     | (72.4) |                           |              |
|                                      | nr     | 488                               | 276                        | (56.6) |                           |              | 353                     | (72.3) |                           |              |
|                                      |        |                                   |                            |        |                           |              |                         |        |                           |              |
|                                      |        |                                   |                            |        |                           |              |                         |        |                           |              |
|                                      |        | Symptomatic infections<br>n=2,005 | Myalgia/arthralgia n=1,148 |        |                           |              | Cough n=1,084           |        |                           |              |
|                                      |        |                                   | n.                         | (%)    | adjOR (95%CI)             | p            | n.                      | (%)    | adjOR (95%CI)             | p            |
| Sex                                  | Female | 1,589                             | 951                        | (59.8) | <b>1.63 (1.31 - 2.04)</b> | <b>0.000</b> | 860                     | (54.1) |                           | ns           |
|                                      | Male   | 416                               | 197                        | (47.4) | ref                       |              | 224                     | (53.8) |                           |              |
| Age class                            | ≤30    | 398                               | 210                        | (52.8) |                           | ns           | 247                     | (62.1) | <b>1.56 (1.19 - 2.05)</b> | <b>0.001</b> |
|                                      | 31-49  | 717                               | 399                        | (55.6) |                           |              | 375                     | (52.3) | 1.07 (0.86 - 1.34)        | 0.548        |
|                                      | >50    | 616                               | 382                        | (62.0) |                           |              | 316                     | (51.3) | ref                       |              |
|                                      | nr     | 274                               | 157                        | (57.3) |                           |              | 146                     | (53.3) |                           |              |
|                                      |        |                                   |                            |        |                           |              |                         |        |                           |              |
| Comorbidities                        | yes    | 460                               | 288                        | (62.6) |                           | ns           | 260                     | (56.5) |                           | ns           |
|                                      | no     | 1,545                             | 860                        | (55.7) |                           |              | 824                     | (53.3) |                           |              |
| Reinfection                          | yes    | 150                               | 69                         |        | <b>0.66 (0.47 - 0.93)</b> | <b>0.018</b> | 69                      | (46.0) | <b>0.56 (0.40 - 0.80)</b> | <b>0.001</b> |
|                                      | no     | 1,855                             | 1,079                      | (58.2) | ref                       |              | 1,015                   | (54.7) | ref                       |              |
| Study phase                          | 1      | 87                                | 57                         | (65.5) |                           | ns           | 35                      | (40.2) | <b>0.24 (0.12 - 0.46)</b> | <b>0.000</b> |
|                                      | 2      | 304                               | 218                        | (71.7) |                           |              | 121                     | (39.8) | <b>0.22 (0.13 - 0.39)</b> | <b>0.000</b> |
|                                      | 3      | 55                                | 27                         | (49.1) |                           |              | 29                      | (52.7) | <b>0.53 (0.29 - 0.97)</b> | <b>0.038</b> |
|                                      | 4      | 601                               | 314                        | (52.2) |                           |              | 293                     | (48.8) | <b>0.49 (0.40 - 0.62)</b> | <b>0.000</b> |
|                                      | 5      | 772                               | 432                        | (56.0) |                           |              | 505                     | (65.4) | ref                       |              |
|                                      | nr     | 186                               | 100                        | (53.8) |                           |              | 101                     | (54.3) |                           |              |
|                                      |        |                                   |                            |        |                           |              |                         |        |                           |              |
| Vaccination status to the positivity | 0      | 356                               | 245                        | (68.8) |                           | ns           | 150                     | (42.1) | 1.60 (0.92 - 2.80)        | 0.097        |
|                                      | 1      | 30                                | 14                         | (46.7) |                           |              | 7                       | (23.3) | <b>0.35 (0.14 - 0.84)</b> | <b>0.019</b> |
|                                      | 2      | 135                               | 74                         | (54.8) |                           |              | 76                      | (56.3) | 1.21 (0.83 - 1.78)        | 0.324        |
|                                      | 3      | 996                               | 541                        | (54.3) |                           |              | 580                     | (58.2) | ref                       |              |
|                                      | nr     | 488                               | 274                        | (56.1) |                           |              | 271                     | (55.5) |                           |              |
|                                      |        |                                   |                            |        |                           |              |                         |        |                           |              |
|                                      |        |                                   |                            |        |                           |              |                         |        |                           |              |

Legend: bold indicates statistically significant results; ns: not significant association; ref: reference; nr: subjects who did not respond to the specific question in the online questionnaire.

**Table S4.** Distribution of COVID-19-related symptoms - Logistic multivariate analysis.

|                                      |        | Symptomatic infections<br>n=2,005 | Headache n=1,048 |        |                    |       | Vomiting n=186         |        |                    |       |
|--------------------------------------|--------|-----------------------------------|------------------|--------|--------------------|-------|------------------------|--------|--------------------|-------|
|                                      |        |                                   | n.               | (%)    | adjOR (95%CI)      | p     | n.                     | (%)    | adjOR (95%CI)      | p     |
| Sex                                  |        |                                   |                  |        |                    |       |                        |        |                    |       |
|                                      | Female | 1,589                             | 885              | (55.7) | 1.94 (1.55 - 2.42) | 0.000 | 173                    | (10.9) | 3.93 (2.2 - 7.03)  | 0.000 |
|                                      | Male   | 416                               | 163              | (39.2) | Ref                |       | 13                     | (3.1)  | ref                |       |
| Age class                            |        |                                   |                  |        |                    |       |                        |        |                    |       |
|                                      | ≤30    | 398                               | 196              | (49.2) |                    | ns    | 32                     | (8.0)  |                    | ns    |
|                                      | 31-49  | 717                               | 386              | (53.8) |                    |       | 62                     | (8.6)  |                    |       |
|                                      | >50    | 616                               | 330              | (53.6) |                    |       | 73                     | (11.9) |                    |       |
|                                      | nr     | 274                               | 136              | (49.6) |                    |       | 19                     | (6.9)  |                    |       |
| Comorbidities                        |        |                                   |                  |        |                    |       |                        |        |                    |       |
|                                      | yes    | 460                               | 251              | (54.6) |                    | ns    | 49                     | (10.7) |                    | ns    |
|                                      | no     | 1,545                             | 797              | (51.6) |                    |       | 137                    | (8.9)  |                    |       |
| Reinfection                          |        |                                   |                  |        |                    |       |                        |        |                    |       |
|                                      | yes    | 150                               | 65               | (43.3) | 0.67 (0.48 - 0.95) | 0.026 | 7                      | (4.7)  | 0.47 (0.21 - 1.04) | 0.061 |
|                                      | no     | 1,855                             | 983              | (53.0) | ref                |       | 179                    | (9.6)  | ref                |       |
| Study phase                          |        |                                   |                  |        |                    |       |                        |        |                    |       |
|                                      | 1      | 87                                | 46               | (52.9) |                    | ns    | 14                     | (16.1) | ref                |       |
|                                      | 2      | 304                               | 175              | (57.6) |                    |       | 42                     | (13.8) | 0.71 (0.36 - 1.39) | 0.313 |
|                                      | 3      | 55                                | 30               | (54.5) |                    |       | 7                      | (12.7) | 0.62 (0.20 - 1.93) | 0.410 |
|                                      | 4      | 601                               | 313              | (52.1) |                    |       | 35                     | (5.8)  | 0.30 (0.11 - 0.83) | 0.020 |
|                                      | 5      | 772                               | 397              | (51.4) |                    |       | 69                     | (8.9)  | 0.54 (0.20 - 1.44) | 0.218 |
|                                      | nr     | 186                               | 87               | (46.8) |                    |       | 19                     | (10.2) |                    |       |
| Vaccination status to the positivity |        |                                   |                  |        |                    |       |                        |        |                    |       |
|                                      | 0      | 356                               | 200              | (56.2) |                    | ns    | 51                     | (14.3) |                    | ns    |
|                                      | 1      | 30                                | 17               | (56.7) |                    |       | 3                      | (10.0) |                    |       |
|                                      | 2      | 135                               | 72               | (53.3) |                    |       | 13                     | (9.6)  |                    |       |
|                                      | 3      | 996                               | 517              | (51.9) |                    |       | 75                     | (7.5)  |                    |       |
|                                      | nr     | 488                               | 242              | (49.6) |                    |       | 44                     | (9.0)  |                    |       |
|                                      |        | Symptomatic infections<br>n=2,005 | Dyspnoea n=419   |        |                    |       | Loss of appetite n=287 |        |                    |       |
|                                      |        |                                   | n.               | (%)    | adjOR (95%CI)      | p     | n.                     | (%)    | adjOR (95%CI)      | p     |
| Sex                                  |        |                                   |                  |        |                    |       |                        |        |                    |       |
|                                      | Female | 1,589                             | 370              | (23.3) | 2.24 (1.61 - 3.11) | 0.000 | 249                    | (15.7) | 1.94 (1.34 - 2.81) | 0.000 |
|                                      | Male   | 416                               | 49               | (11.8) | ref                |       | 38                     | (9.1)  | ref                |       |
| Age class                            |        |                                   |                  |        |                    |       |                        |        |                    |       |
|                                      | ≤30    | 398                               | 71               | (17.8) |                    | ns    | 60                     | (15.1) |                    | ns    |
|                                      | 31-49  | 717                               | 129              | (18.0) |                    |       | 94                     | (13.1) |                    |       |
|                                      | >50    | 616                               | 155              | (25.2) |                    |       | 99                     | (16.1) |                    |       |
|                                      | nr     | 274                               | 64               | (23.4) |                    |       | 34                     | (12.4) |                    |       |
| Comorbidities                        |        |                                   |                  |        |                    |       |                        |        |                    |       |
|                                      | yes    | 460                               | 137              | (29.8) | 1.82 (1.41 - 2.34) | 0.000 | 68                     | (14.8) |                    | ns    |
|                                      | no     | 1,545                             | 282              | (18.3) |                    |       | 219                    | (14.2) |                    |       |
| Reinfection                          |        |                                   |                  |        |                    |       |                        |        |                    |       |
|                                      | yes    | 150                               | 19               | (12.7) |                    | ns    | 9                      | (6.0)  | 0.39 (0.19 - 0.80) | 0.010 |
|                                      | no     | 1,855                             | 400              | (21.6) |                    |       | 278                    | (15.0) | ref                |       |
| Study phase                          |        |                                   |                  |        |                    |       |                        |        |                    |       |
|                                      | 1      | 87                                | 30               | (34.5) | 2.98 (1.45 - 6.10) | 0.003 | 26                     | (29.9) | 2.40 (1.12 - 5.16) | 0.025 |
|                                      | 2      | 304                               | 113              | (37.2) | 3.06 (1.66 - 5.63) | 0.000 | 70                     | (23.0) | 1.54 (0.79 - 3.03) | 0.207 |
|                                      | 3      | 55                                | 10               | (18.2) | 1.13 (0.52 - 2.44) | 0.757 | 10                     | (18.2) | 1.10 (0.50 - 2.41) | 0.820 |
|                                      | 4      | 601                               | 112              | (18.6) | 1.25 (0.93 - 1.68) | 0.136 | 48                     | (8.0)  | 0.45 (0.31 - 0.65) | 0.000 |
|                                      | 5      | 772                               | 116              | (15.0) | ref                |       | 119                    | (15.4) | ref                |       |
|                                      | nr     | 186                               | 38               | (20.4) |                    |       | 14                     | (7.5)  |                    |       |
| Vaccination status to the positivity |        |                                   |                  |        |                    |       |                        |        |                    |       |
|                                      | 0      | 356                               | 124              | (34.8) |                    | ns    | 84                     | (23.6) |                    | ns    |
|                                      | 1      | 30                                | 6                | (20.0) |                    |       | 1                      | (3.3)  |                    |       |
|                                      | 2      | 135                               | 24               | (17.8) |                    |       | 18                     | (13.3) |                    |       |
|                                      | 3      | 996                               | 160              | (16.1) |                    |       | 122                    | (12.2) |                    |       |
|                                      | nr     | 488                               | 105              | (21.5) |                    |       | 62                     | (12.7) |                    |       |

Legend: bold indicates statistically significant results; ns: not significative association; ref: reference; nr: subjects who did not respond to the specific question in the online questionnaire.

**Table S5.** Distribution of COVID-19-related symptoms - Logistic multivariate analysis.

|                                             |        | Symptomatic infections<br>n=2,005 | Loss of taste n=525 |        |                             |              | Loss of smell n=501 |        |                            |              |
|---------------------------------------------|--------|-----------------------------------|---------------------|--------|-----------------------------|--------------|---------------------|--------|----------------------------|--------------|
|                                             |        |                                   | n.                  | (%)    | adjOR (95%CI)               | p            | n.                  | (%)    | adjOR (95%CI)              | p            |
| <b>Sex</b>                                  | Female | 1,589                             | 437                 | (27.5) | <b>1.40 (1.06 - 1.85)</b>   | <b>0.018</b> | 406                 | (25.6) |                            | ns           |
|                                             | Male   | 416                               | 88                  | (21.2) | ref                         |              | 95                  | (22.8) | ref                        |              |
| <b>Age class</b>                            | ≤30    | 398                               | 84                  | (21.1) |                             | ns           | 91                  | (22.9) |                            | ns           |
|                                             | 31-49  | 717                               | 186                 | (25.9) |                             |              | 179                 | (25.0) |                            |              |
|                                             | >50    | 616                               | 178                 | (28.9) |                             |              | 154                 | (25.0) |                            |              |
|                                             | nr     | 274                               | 77                  | (28.1) |                             |              | 77                  | (28.1) |                            |              |
| <b>Comorbidities</b>                        | yes    | 460                               | 131                 | (28.5) |                             | ns           | 115                 | (25.0) |                            | ns           |
|                                             | no     | 1,545                             | 394                 | (25.5) |                             |              | 386                 | (25.0) |                            |              |
| <b>Reinfection</b>                          | yes    | 150                               | 18                  | (12.0) | <b>0.50 (0.30 - 0.84)</b>   | <b>0.009</b> | 15                  | (10.0) | <b>0.43 (0.25 - 0.76)</b>  | <b>0.004</b> |
|                                             | no     | 1,855                             | 507                 | (27.3) | ref                         |              | 486                 | (26.2) | ref                        |              |
| <b>Study phase</b>                          | 1      | 87                                | 49                  | (56.3) | <b>10.38 (5.12 - 21.01)</b> | <b>0.000</b> | 53                  | (60.9) | <b>9.89 (4.90 - 19.96)</b> | <b>0.000</b> |
|                                             | 2      | 304                               | 166                 | (54.6) | <b>9.42 (5.10 - 17.41)</b>  | <b>0.000</b> | 171                 | (56.3) | <b>8.05 (4.39 - 14.78)</b> | <b>0.000</b> |
|                                             | 3      | 55                                | 22                  | (40.0) | <b>3.53 (1.84 - 6.77)</b>   | <b>0.000</b> | 21                  | (38.2) | <b>3.07 (1.59 - 5.92)</b>  | <b>0.001</b> |
|                                             | 4      | 601                               | 110                 | (18.3) | <b>1.08 (0.81 - 1.44)</b>   | <b>0.610</b> | 101                 | (16.8) | <b>1.14 (0.85 - 1.55)</b>  | <b>0.383</b> |
|                                             | 5      | 772                               | 127                 | (16.5) | ref                         |              | 108                 | (14.0) | ref                        |              |
|                                             | nr     | 186                               | 51                  | (27.4) |                             |              | 47                  | (25.3) |                            |              |
| <b>Vaccination status to the positivity</b> | 0      | 356                               | 186                 | (52.2) |                             | ns           | 198                 | (55.6) | 0.97 (0.52 - 1.79)         | 0.916        |
|                                             | 1      | 30                                | 8                   | (26.7) |                             |              | 8                   | (26.7) | 1.45 (0.59 - 3.59)         | 0.417        |
|                                             | 2      | 135                               | 36                  | (26.7) |                             |              | 36                  | (26.7) | <b>1.95 (1.24 - 3.06)</b>  | <b>0.004</b> |
|                                             | 3      | 996                               | 176                 | (17.7) |                             |              | 147                 | (14.8) | ref                        |              |
|                                             | nr     | 488                               | 119                 | (24.4) |                             |              | 112                 | (23.0) |                            |              |

Legend: bold indicates statistically significant results; ns: not significative association; ref: reference; nr: subjects who did not respond to the specific question in the online questionnaire.